Folic acid (Vitamin B9) is the water-soluble vitamin mainly found in the foods and supplements, which is involved in the synthesis and repair of DNA and RNA, aiding rapid cell division and growth, enhancing the overall brain health, etc. in the body. In this study, the impact of the Trivedi Effect®-Consciousness Energy Healing Treatment on the structural properties and the isotopic abundance ratio of folic acid was investigated using LC-MS spectroscopy. The test sample folic acid was divided into control and treated parts. Only the treated part received the Trivedi Effect®-Consciousness Energy Healing Treatment remotely by a renowned Biofield Energy Healer, Dahryn Trivedi. The chromatographic spectra of both the samples exhibited the same retention time at 1.8 minutes and mass of the molecular ion peak at 441.92 (calcd for C19H20N7O6+, 442.15) along with low molecular fragmented mass peaks at m/z 295.08, 267, 250.17, and 207.92 for C14H11N6O2+, C12H15N2O5+, C12H12NO5+, and C11H14NO3+, respectively were also observed. The peak area of the treated folic acid (6029494.3) was increased by 1.12% compared to the control sample (5963001.45). The isotopic abundance ratio of PM+1/PM (2H/1H or 13C/12C or 15N/14N or 17O/16O) in the treated folic acid was significantly increased by 81.37% compared with the control sample. Hence, the 13C, 2H, 15N, and 17O contributions from C19H20N7O6+ to m/z 442.92 in the treated sample were significantly increased compared with the control sample. The changes in isotopic abundance and mass peak intensities might occur due to the changes in nuclei possibly through the interference of neutrino particles via the Trivedi Effect®-Consciousness Energy Healing Treatment. The increased isotopic abundance ratio and peak area of the treated folic acid may increase the chemical bond strength, increase its stability, improve solubility, and bioavailability in the body. The new form of Biofield Energy Treated folic acid could be used for designing novel pharmaceutical formulations that might offer better therapeutic response against embryonic defects, clinical depression, megaloblastic anemia, altered memory, and brain function, leuco- and thrombocytopenia, malignancies, neural tube defects, depression, allergic diseases, cardiovascular disease, and lower bone density, etc.
